— Know what they know.
Not Investment Advice

AMRS NASDAQ

Amyris, Inc.
1W: +10.5% 1M: -54.9% 3M: -96.4% 1Y: -98.9% 3Y: -98.6% 5Y: -99.5%
$0.05
Last traded 2023-09-13 — delisted
NASDAQ · Basic Materials · Chemicals - Specialty
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.0M
52W Range0.05-0.0643
Volume46,746,028
Avg Volume46,746,028
Beta1.19
Dividend—
Analyst Ratings
9 Buy 9 Hold 2 Sell
Consensus Buy
Company Info
CEOHermanus Kieftenbeld
Employees1,598
SectorBasic Materials
IndustryChemicals - Specialty
IPO Date2010-09-28
Websiteamyris.com
5885 Hollis Street
EmeryVille, CA 94608
US
510 450 0761
About Amyris, Inc.

Amyris, Inc. is a synthetic biotechnology enterprise with global operations in the clean health, beauty, and flavors and fragrance sectors, covering Europe, North America, Asia, and South America. The company produces and sells a variety of consumer goods, including clean beauty, personal care, and health and wellness products, as well as specialized ingredients supplied to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care industries. Its product offerings are marketed under brand names such as Biossance, Pipette, Purecane, Terasana, Costa Brazil, OLIKA, Rose Inc., and JVN. Amyris also engages in a collaborative agreement with the Infectious Disease Research Institute for the advancement of a COVID-19 vaccine. Founded in 2003 and based in Emeryville, California, the company operated as Amyris Biotechnologies, Inc. until it adopted its current name, Amyris, Inc., in June 2010.

Latest News
No recent news

Recent Insider Trades

NameTypeSharesPriceDate
MILLS STEVEN RICHARD J-Other 10,316 — 2024-05-07
DUYK GEOFFREY M J-Other 40,552 — 2024-05-07
Kung Frank J-Other 16,207 — 2024-05-07
Washington Julie J-Other 19,166 — 2024-05-07
Dutra Ana J-Other 10,950 — 2024-05-07

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms